Ovid Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on a Special Meeting of stockholders held by Ovid Therapeutics Inc. on December 11, 2025. The filing details the voting results for three proposals regarding capital structure and securities issuance.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the record date (October 31, 2025), there were 71,212,353 shares of Common Stock outstanding. A quorum was established with 38,044,680 shares (53.42%) present. Stockholders approved the following proposals:
- Proposal 1: Increase in Authorized Shares
- Amended the Certificate of Incorporation to increase authorized Common Stock from 125,000,000 to 315,000,000 shares.
- Votes: 34,225,378 For; 1,453,502 Against; 2,365,800 Abstain.
- Proposal 2: Conversion of Preferred Stock and Exercise of Warrants
- Approved issuance of Common Stock upon conversion of Series B Preferred Stock and exercise of Series A and Series B Warrants to comply with Nasdaq Listing Rule 5635(d).
- Votes: 34,251,878 For; 1,327,426 Against; 2,465,376 Abstain.
- Proposal 3: Issuance of Securities to Executive Officer
- Approved issuance and sale of Series B Preferred Stock, Series A Warrants, and Series B Warrants to CEO Jeremy Levin pursuant to a Securities Purchase Agreement dated October 2, 2025, to comply with Nasdaq Listing Rule 5635(c).
- Votes: 34,335,202 For; 1,225,141 Against; 2,484,337 Abstain.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or specific risk factors beyond the context of complying with Nasdaq listing rules for the proposed issuances.
Investor Verification Checklist
- Verify the impact of the increased authorized share count (315,000,000) on potential future dilution.
- Review the definitive proxy statement filed on November 7, 2025, for detailed terms of the Series B Preferred Stock and Warrants.
- Confirm the specific terms of the Securities Purchase Agreement dated October 2, 2025, regarding the issuance to CEO Jeremy Levin.
- Monitor subsequent filings for the actual issuance of shares resulting from the approved conversions and warrant exercises.